Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Results entities : Merck & company, inc. save search
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 2.37%
H: 1.46%
C: 1.22%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.6%
HTGC F | $18.46 1.15% 0.38% 660K
|
Finance
|
| O: -2.77%
H: 0.47%
C: -0.27%
VKTX | $63.38 -2.0% -2.04% 3M
|
Health Technology
|
| O: 81.31%
H: 29.0%
C: 21.9%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 2.1%
H: 2.83%
C: -0.5%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: 14.46%
H: 11.02%
C: 4.72%
ALDX | News | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.91%
H: 2.68%
C: 1.07%
year financial results
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.37%
H: 0.0%
C: 0.0%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.38%
H: 2.25%
C: 2.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.15%
H: 0.1%
C: -1.86%
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
merck financial results
Merck Announces Third-Quarter 2023 Financial Results
Published: 2023-10-26 (Crawled : 11:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.51%
H: 4.0%
C: 2.38%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.04%
H: 0.64%
C: -0.98%
merck financial results
Merck Announces First-Quarter 2023 Financial Results
Published: 2023-04-27 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.03%
H: 0.66%
C: 0.49%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.13%
H: 1.05%
C: -0.63%
merck financial results
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 7.92%
H: 0.0%
C: 0.0%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.8%
H: 0.6%
C: -0.29%
propel symposium trial results
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.22%
H: 0.0%
C: -1.61%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -2.77%
H: 1.72%
C: -0.54%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.37%
H: 1.07%
C: 0.66%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.52%
H: 1.92%
C: 1.7%
financial results
Merck Announces Third-Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 11:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.45%
H: 1.66%
C: -0.1%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.97%
H: 2.0%
C: 0.51%
financial results
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
Published: 2022-09-12 (Crawled : 13:20) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.71%
H: 0.14%
C: -1.05%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.9%
H: 1.17%
C: 0.03%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -3.57%
padcev trial results cancer
Merck Announces First-Quarter 2022 Financial Results
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.96%
H: 0.0%
C: 0.0%
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.36%
H: 0.0%
C: 0.0%
results
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
Published: 2022-04-21 (Crawled : 12:20) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
conference report results
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
Published: 2022-02-17 (Crawled : 13:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.48%
H: 0.1%
C: -0.64%
report results
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
Published: 2022-02-03 (Crawled : 13:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.27%
H: 0.18%
C: -3.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
financial results ces results
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
Published: 2022-02-01 (Crawled : 13:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.04%
H: 0.19%
C: -0.05%
conference report results
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
Published: 2022-01-20 (Crawled : 13:30) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.31%
H: 1.4%
C: 0.02%
ynote-775 keytruda trial results phase 3
Organon Reports Results for the Third Quarter Ended September 30, 2021
Published: 2021-11-11 (Crawled : 16:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.11%
H: 0.41%
C: 0.12%
results
Acceleron Reports Third Quarter 2021 Financial Results
Published: 2021-11-04 (Crawled : 21:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.8%
H: 1.14%
C: 0.19%
financial results results
Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.26%
H: 4.17%
C: 3.8%
results conference
Merck Announces Third-Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.26%
H: 4.17%
C: 3.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.2%
C: 0.32%
financial results results
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.1%
H: 0.86%
C: 0.78%
treatment positive results trials phase 3 trial hiv topline injection infections
Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend
Published: 2021-08-12 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.12%
H: 1.25%
C: 1.22%
results
Gainers vs Losers
| 68% | 32% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.